Role of Immediate early gene induction and AP-1 activation in HDAC inhibitor induced apoptosis.

组蛋白去乙酰酶抑制剂(HDACi)是一类新型的抗肿瘤药物，最近被批准用于治疗皮肤T细胞淋巴瘤。这项研究的目的是提高我们对这类药物如何诱导肿瘤细胞死亡的理解。这些研究旨在深入了解哪些患者最有可能从这些药物的治疗中受益。其次，它们将为如何通过与其他现有疗法相结合来提高HDACi的治疗效果提供指导。

Histone deacetylase inhibitors (HDACi) are a novel class of anti-tumor agents, recently approved for the treatment of cutaneous T-cell lymphoma. The goal of this study is to improve our understanding of how this class of drug induces tumor cell death. These studies are designed to provide insight into which patients are most likely to benefit from treatment with these agents. Second, they will provide direction into how the therapeutic efficacy of HDACi may be enhanced, through combination with other existing therapeutics.